VaxGen

From Wikipedia, the free encyclopedia

VaxGen is a biopharmaceutical company based in the San Francisco Bay Area.

Contents

[edit] AIDSVAX

In 1990s VaxGen developed, and began trials of, an AIDS vaccine called AIDSVAX. However, in 2003 it was announced that the preliminary trials of the vaccine, conducted in Thailand, had been unsuccessful.

[edit] Current development

VaxGen is currently attempting to develop vaccines to combat Smallpox, Anthrax and Meningitis B.

[edit] Anthrax vaccine

Vaxgen had focused its recent efforts on a new form of Anthrax Vaccine, for which it was awarded a $877 million dollar contract. In December of 2006, HHS unilaterally withdrew the $877 million dollar contract, sending the stock tumbling as low as $1.20 per share. The stock vxgn.pk has since recovered on talk that Vaxgen is preparing itself for sale to a larger entity who could capitalize on vaccine facility.

[edit] External links

  This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../v/a/x/VaxGen_8710.html"